180 related articles for article (PubMed ID: 24680675)
1. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds.
Rangel-Barajas C; Malik M; Vangveravong S; Mach RH; Luedtke RR
Neuropharmacology; 2014 Aug; 83():18-27. PubMed ID: 24680675
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds.
Rangel-Barajas C; Malik M; Mach RH; Luedtke RR
Neuropharmacology; 2015 Jun; 93():179-90. PubMed ID: 25698528
[TBL] [Abstract][Full Text] [Related]
3. The effect of the sigma-1 receptor selective compound LS-1-137 on the DOI-induced head twitch response in mice.
Malik M; Rangel-Barajas C; Mach RH; Luedtke RR
Pharmacol Biochem Behav; 2016 Sep; 148():136-44. PubMed ID: 27397487
[TBL] [Abstract][Full Text] [Related]
4. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen.
Canal CE; Olaghere da Silva UB; Gresch PJ; Watt EE; Sanders-Bush E; Airey DC
Psychopharmacology (Berl); 2010 Apr; 209(2):163-74. PubMed ID: 20165943
[TBL] [Abstract][Full Text] [Related]
5. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
[TBL] [Abstract][Full Text] [Related]
6. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
Zhang W; Bymaster FP
Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
[TBL] [Abstract][Full Text] [Related]
7. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice.
McNamara RK; Levant B; Taylor B; Ahlbrand R; Liu Y; Sullivan JR; Stanford K; Richtand NM
Neuroscience; 2006 Nov; 143(1):141-53. PubMed ID: 16938406
[TBL] [Abstract][Full Text] [Related]
8. Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT
de la Fuente Revenga M; Jaster AM; McGinn J; Silva G; Saha S; González-Maeso J
ACS Chem Neurosci; 2022 Aug; 13(16):2436-2448. PubMed ID: 35900876
[TBL] [Abstract][Full Text] [Related]
9. Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats.
Zhang M; Ballard ME; Kohlhaas KL; Browman KE; Jongen-Rêlo AL; Unger LV; Fox GB; Gross G; Decker MW; Drescher KU; Rueter LE
Neuropsychopharmacology; 2006 Jul; 31(7):1382-92. PubMed ID: 16395300
[TBL] [Abstract][Full Text] [Related]
10. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats.
Willins DL; Meltzer HY
J Pharmacol Exp Ther; 1997 Aug; 282(2):699-706. PubMed ID: 9262333
[TBL] [Abstract][Full Text] [Related]
11. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ
J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755
[TBL] [Abstract][Full Text] [Related]
12. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.
Canal CE; Booth RG; Morgan D
Neuropharmacology; 2013 Jul; 70():112-21. PubMed ID: 23353901
[TBL] [Abstract][Full Text] [Related]
13. Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (+/- )-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin.
Darmani NA; Martin BR; Glennon RA
J Pharmacol Exp Ther; 1992 Aug; 262(2):692-8. PubMed ID: 1501117
[TBL] [Abstract][Full Text] [Related]
14. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Substituted
Lee B; Taylor M; Griffin SA; McInnis T; Sumien N; Mach RH; Luedtke RR
Molecules; 2021 May; 26(11):. PubMed ID: 34073405
[No Abstract] [Full Text] [Related]
16. A study of the structure-affinity relationship in SYA16263; is a D
Onyameh EK; Bricker BA; Eyunni SVK; Voshavar C; Gonela UM; Ofori E; Jenkins A; Ablordeppey SY
Bioorg Med Chem; 2021 Jan; 30():115943. PubMed ID: 33338898
[TBL] [Abstract][Full Text] [Related]
17. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
[TBL] [Abstract][Full Text] [Related]
18. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.
Assié MB; Bardin L; Auclair A; Consul-Denjean N; Sautel F; Depoortère R; Newman-Tancredi A
Naunyn Schmiedebergs Arch Pharmacol; 2007 Jun; 375(4):241-50. PubMed ID: 17453175
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.
Luedtke RR; Mishra Y; Wang Q; Griffin SA; Bell-Horner C; Taylor M; Vangveravong S; Dillon GH; Huang RQ; Reichert DE; Mach RH
ACS Chem Neurosci; 2012 Dec; 3(12):1050-62. PubMed ID: 23259040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]